Ep201: Jeremy Levin on Biotech in the Balance

Episode Summary

Executive Summary: Jeremy Levin argues biotech is in a trust crisis caused by years of blurred identity with pharma, politicized science, and weak industry self-defense. He says the result is hostile policy, fragile capital formation, and risk of innovation migrating abroad. His remedy is a practical code: scientific truth, patient primacy, transparency, ethical development, regulatory integrity, and long-term capital and manufacturing support.

Main Topics: Why Levin wrote the book now (Priority: 5/5): Levin explains that the book grew out of earlier COVID-era reflections and a recent sense that biotech faces a broader, urgent system-level threat. He wanted a rapid, constructive response rather than a complaint list. Biotech’s public trust problem (Priority: 5/5): The industry’s long-standing confusion with pharma, especially around drug pricing and access, has made biotech a political target and left the public unable to distinguish innovative biotech from large pharmaceutical companies. Politics, COVID, and accelerated distrust (Priority: 5/5): Levin says Shkreli was a warning sign, but COVID massively amplified distrust through misinformation, politicization of vaccines, and weak public communication about what science knew and did not know. Policy and institutional damage (Priority: 5/5): He argues that cuts to NIH, upheaval at FDA, and science skepticism at CDC and HHS have created a destabilizing environment that threatens the U.S. innovation ecosystem. The 10 commitments as a reset framework (Priority: 5/5): Levin presents practical commitments aimed at restoring trust: scientific truth, patient primacy, ethical development, transparency, regulatory integrity, and long-term capital formation. Capital formation and long-term incentives (Priority: 4/5): He says biotech is mismatched with short-term markets and needs longer-horizon financing, simpler reporting, and policy tools that reward patient capital rather than quarterly trading. Manufacturing, resilience, and strategic competition with China (Priority: 4/5): Levin emphasizes that biotech manufacturing should be treated as strategic infrastructure, with domestic capacity, redundancy, and innovation in manufacturing methods to avoid dependency and supply shocks.

Key Arguments: Biotech became politically vulnerable because the public largely sees it as interchangeable with pharma, especially on pricing and access issues. The industry should have responded more forcefully to Shkreli-era pricing outrage and to COVID-era misinformation with clearer public messaging. COVID vaccines were a major scientific achievement, but the public was not given a simple, trustworthy explanation of benefits, limits, and risk. The U.S. scientific ecosystem is being weakened by instability at NIH, FDA, CDC, and HHS, which threatens innovation and investment confidence. Biotech needs to define itself as a strategic industry similar to semiconductors or energy, not as a generic subset of pharma. Long-term capital is essential because biotech development takes years and cannot be fixed on the fly like software or consumer tech. Transparency in trial results, risks, failures, and limitations is necessary because patient participation and investor trust depend on it. Manufacturing resilience and domestic capacity are ethical and strategic necessities, not optional costs. China has treated biotech as a strategic national project, creating a competitive challenge the U.S. is not yet meeting. Industry-led public education and advertising could help rebuild trust if it explains science in plain language and focuses on patient benefit.

Data Points: CEOs and others writing chapters in earlier book project: 47 - Levin’s first biotech book project during the COVID era People in the room at the Greece conference: 100 - Conference where Levin asked CEOs to write about the industry’s worries Essays produced in six weeks: 6 - Initial response to the new book project was too small to complete a volume Share of drugs produced from biotech: 70% - Levin says roughly 70% of all drugs come from biotech FDA leadership turnover: 90% - Levin cites change in FDA leaders over about a year and a bit as destabilizing COVID deaths in the U.S. referenced: 1.3 million - Levin describes this as the silent graveyard of the pandemic Estimated deaths without vaccines referenced: 10 to 15 million - Levin estimates what might have happened absent vaccination Time horizon for regaining predictability: 3 to 5 years, maybe 10 years - Levin says restoring stable markets and regulatory predictability will take years Years of biotech industry emergence: 40 to 50 years - He describes biotech as built on decades of science and entrepreneurship Five-point China biotech plan: 5 points - Levin outlines China’s staged strategic plan for biotech dominance J&J historical return example: About $40,000 for every $1 invested - Used to illustrate long-term capital formation benefits Current public approval level for industry: Below 10% (described qualitatively) - Luke says trust/approval has remained extremely low since COVID

Pivotal Quotes: "We’re running the risk of killing the golden goose." — Jeremy Levin: On public hostility and policy pressure threatening U.S. biotech innovation "If truth becomes negotiable, everything downstream collapses." — Jeremy Levin: On scientific truth as the first commitment and foundation of trust "Innovation won’t stop. It’ll just migrate." — Jeremy Levin: On the risk that capital and talent will move outside the United States if conditions worsen

Implications: Biotech must actively rebuild trust or risk losing capital, talent, and leadership to better-prepared countries. The industry’s future depends on clearer public communication, stronger institutions, and policies that reward long-term innovation over short-term extraction.